Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Isaac See et al.
Summary: Cases of CVST with thrombocytopenia following Ad26.COV2.S vaccination have been reported in the US, leading to serious outcomes. This case series may provide guidance for clinical management and further investigation into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Marie Scully et al.
Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Douglas B. Cines et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Andreas Greinacher et al.
Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Marc E. Wolf et al.
Summary: The study focused on clinical manifestations and management of patients with cranial venous sinus thrombosis following exposure to the COVID-19 vaccine AstraZeneca, showing that these patients shared similarities in diagnosis and treatment processes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Letter
Medicine, General & Internal
Swathi Sangli et al.
ANNALS OF INTERNAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Jimin Hwang et al.
Summary: Fibrinogen levels, age, platelet count, and the presence of intracerebral hemorrhage and cerebral venous thrombosis were found to be significantly associated with mortality in adenoviral vaccine-associated thrombosis with thrombocytopenia syndrome (TTS). The newly developed FAPIC scoring system incorporating these risk factors showed promising predictive value for mortality in patients with TTS.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Sverre Holm et al.
Summary: The study revealed that the formation of thrombus in VITT patients is associated with massive innate immune activation, particularly the activation of neutrophils including NETosis. These findings suggest a potential relationship between VITT pathogenesis and abnormal immune response.
EUROPEAN HEART JOURNAL
(2021)
Editorial Material
Hematology
Daniela P. Mendes-de-Almeida et al.
Article
Medicine, General & Internal
Sue Pavord et al.
Summary: Phenotypes of VITT were defined in 220 patients in the United Kingdom who presented a median of 14 days after the first ChAdOx1 nCoV-19 vaccination. Half had cerebral venous sinus thrombosis, a third of whom also had intracranial hemorrhage. Mortality was 22%. Intravenous immune globulin may reverse VITT.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
